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doi:10.1016/j.ejvs.2009.09.015Abstract Objectives: The long-term outcome of catheter-directed thrombolysis (CDT) in
patients with acute iliofemoral venous thrombosis (IFVT) is evaluated in this study.
Material and methods: Patients presenting for treatment with IFVT between June 1999 and
May 2007 were considered for treatment using CDT. The following inclusion criteria were used:
first episode of IFVT, age below 60 years, age of thrombus <14 days and open distal popliteal
vein. Ultrasonography (US) was used to verify the diagnosis. The popliteal vein was punctured
under local anaesthesia using US guidance, and a multi-side-hole catheter with tip occlusion
was placed in the thrombus. A solution of r-TPA was infused either continuously or using the
pulse spray technique together with heparin. Any occlusion or residual stenosis in the iliac vein
system was treated by stenting.
Compression stockings and anticoagulation treatment were given for at least 12 months.
Patients with severe thrombophilias were treated for longer periods. The patients were
assessed by colour-duplex US for assessment of patency and valve function after 6 weeks, 3,
6 and 12 months and afterwards on a yearly basis.
Results: A total of 101 patients with 103 extremities affected by iliofemoral venous thrombosis
were included (median age; 29 years, 78 women, and 79 had left-sided thrombosis). A stent
was inserted in 57 limbs. The median follow-up time was 50 months (range 3 dayse108
months). At 6 years, 82% of the limbs had patent veins with competent valves and without
any skin changes or venous claudication.
Conclusion: Treatment with CDT for IFVT achieves good patency and vein function after 6
years of follow-up in this highly selected group of patients. We suggest that results from9 77 75 08; fax: þ 45 39 77 76 74.
t.dk (N. Bækgaard).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Catheter-directed Thrombolysis of IF DVT 113future studies should be presented as KaplaneMeier plots using venous patency without
reflux as the main outcome, since it is an early indicator of the clinical outcome.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights
reserved.Table 1 Inclusion and exclusion criteria for catheter-
directed thrombolysis of acute iliofemoral venous throm-
bosis (IFVT).
Inclusion criteria Exclusion criteria
First episode
of IFVT
Previous ipsilateral DVT
Age< 60 years Major surgery in the
last week
Age of thrombus< 14 days Birth in the last week
Open distal part of the
popliteal vein
Pregnancy
Cancer
Severe hypertension
Recent gastrointestinal
bleeding
Recent cerebral
hemorrhage
Aplasia of IVCAcute deep venous thrombosis, especially in the iliofe-
moral segment, is the cause of significant morbidity if left
untreated. The thrombus may cause venous obstruction
and/or valve insufficiency, which in time can lead to post-
thrombotic syndrome with disabling venous claudication
and skin damage and with severely impaired quality of
life.
Endovenous treatments for venous thrombosis have been
developed in the past 20 years. These aim to remove the
thrombus in patients with acute deep venous thrombosis,
especially in the iliofemoral segment. Catheter-directed
thrombolysis (CDT) of iliofemoral venous thrombosis (IFVT)
was the first of these new methods and was described in
1991 by Okrent et al.,1 and 3 years later by Semba et al.2
The aim of the method is to restore the venous lumen and
save the valves.3 Early restoration of normal veins tends to
prevent chronic venous insufficiency and might minimise
the risk for post-thrombotic symptoms, in the form of
oedema, venous claudication, eczema or venous ulcera-
tion. These often disabling complications are seen in at
least half of the patients with iliofemoral vein thrombosis,
if treated by anticoagulation alone.4,5 The first review
from1999 showed promising early results, focussing mostly
on the feasibility of the method, in terms of patency of the
treated vein segments.6
This study presents the long-term results from Copen-
hagen with CDT for IFVT.
Patients and Methods
Patients included in this series are all consecutive patients
with acute IFVT treated by CDT at the Gentofte Hospital
from June 1999 to May 2007. The experience with the first
45 patients of this series in Copenhagen has previously been
published.7 Data were collected prospectively, but sup-
plemented with some retrospective clinical data. The
patients were selected for treatment according to the
inclusion and exclusion criteria listed in Table 1. Informa-
tion about the treatment, its purpose and its possible
adverse effects in the form of a small risk of pulmonary
embolism, systemic and local bleeding was given to the
patients initially, and informed consent was obtained. No
patient refused treatment with CDT. All patients were
managed by dedicated staff in the vascular department
without the need for intensive care unit facilities.
The method of CDT and the follow-up programme used
at the Gentofte Hospital has previously been described in
detail.7 Table 2 contains an overview of the method, which
has been practiced in our clinic. In patients where floating
thrombus was seen in the infrarenal inferior vena cava,
retrievable inferior vena cava filter (Gu¨nther Temporary
Vena Cava Filter, Cook Medical), inserted from the
contralateral common femoral vein, was used.
All patients were followed up in the outpatient clinic
by clinical examination, supplemented by ultrasoundexamination of vein patency and valve function, as previ-
ously described. Patients were seen after 6 weeks, 3, 6 and
12 months and yearly thereafter.
Follow-up
All patients were followed up according to the protocol
with exception of two patients, who moved out of Denmark
and were lost to follow-up after 3 and 17 months, respec-
tively. They both had patent veins with competent valves at
the last known follow-up. The median follow-up time for
the entire series was 50 months (range 3 dayse108 months).
Endpoints and statistics
The ultimate endpoint was the development of post-
thrombotic syndrome (PTS), especially venous claudication
and skin changes. Since PTS can develop after several years
with none or only mild symptoms, we chose to include the
surrogate endpoint ‘patent vein without reflux’, the ratio-
nale being that in a patient with an open vein without reflux
is it unlikely that PTS will develop. Survival analysis with
KaplaneMeier curves was used for this endpoint.
Secondary endpoints were the development of compli-
cations, especially re-thrombosis, pulmonary embolism (PE)
and bleeding complications.
Statistical analysis was performed using STATA, version
10.0 (StataCorp, College Station, TX, USA).
Results
A total of 101 consecutive patients with acute IFVT
affecting 103 lower extremities were included in the study.
All patients were treated according to the protocol,
Table 2 The technique of CDT.
Puncture of distal popliteal vein
Guidance with US
Multi-side-hole catheter
with tip occlusion
Bolus rt-PA 10 mg, rt-PA 1,2 mg/h
APTT adjusted to 80e100 s
Infusion volumen 120 ml/h
Continuous/pulse spray
Daily venogram
Intermittent pneumatic compression
Stent if a residual stenosis is seen
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Figure 1
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inclusion and exclusion criteria.
The median age was 29 years (range 15e59 years), male/
female ratio 23/78 and left/right ratio was 79/24. A self-
expandable stent (Wall Stent, Boston Scientific) was placed
on the left side in 55 cases and on the right side in two cases.
Symptomatic PE was diagnosed with perfusioneventilation
lung scintigraphy before treatment in six patients.
A retrievable vena cava filter (Cook Medical) was inser-
ted in seven patients and immediately removed after
a successful thrombolytic procedure.
One male presenting with bilateral IFVT was diagnosed
following treatment with testicular cancer and retroperi-
toneal metastases. The initial abdominal ultrasound
examination did not reveal any abnormality, but a later
computed tomography (CT) scan showed glandular tumour
along the spine. Thrombophilia was seen in 54% of the
patients, mainly factor V Leiden mutation, 35% used
contraceptive pills and 22% were post partum. The median
treatment time was 58 h.
Complications
No deaths occurred in this series following treatment. One
patient was suspected of having a PE during treatment, but
the ventilationeperfusion lung scintigraphy was normal. In
two patients the procedure had to be terminated. One
patient, due to septicaemia without a known focus, was
started on antibiotic treatment, and the thrombolytic
treatment continued the next day. In another patient,
development of an acute haematoma in the forearm
necessitated fasciotomy. On the following day, phlebog-
raphy of the iliofemoral segment was normal. A few weeks
later, the patient recovered fully. This serious complication
was a result of an arterial puncture in the radial artery at
the wrist a few days before thrombolysis. Two patients
developed mild erythema and three patients had a small
haematoma in the popliteal fossa, which did not need
treatment. In several cases, slight bleeding along the
catheter in the popliteal fossa was seen and managed with
a simple compression bandage.
One patient complained of pain in the right groin in the
sitting position some years after the treatment. A duplex
scan showed that the open stent covered the proximal part
of the common femoral vein. This was confirmed by the
original venogram after placing the iliac vein stent 3½ years
earlier. We suspected an association between pain and theposition of the stent. The stent was removed and a 10-mm
rPTFE graft was placed end to end as a new conduit. The
pain disappeared later.
Failures with occlusion/stenosis
In one patient with bilateral iliofemoral thrombosis (the
patient with cancer) bilateral CDT was unsuccessful. Four
patients presented with chronic lesions; in three patients it
was impossible to resolve the thrombosed femoral vein
segment. These cases were considered to be chronic
occlusions after earlier asymptomatic DVT, an assumption
based on re-opened collaterals seen on the venogram. In
the fourth patient, a long stenotic lesion with irregularity of
the vein wall was the result after thrombolysis.
Three patients suffered re-occlusion of the iliac vein
within 1 week of thrombolysis. For two of the patients, no
further attempt was made to resolve the thrombus. One
patient had re-thrombosis of her iliac stent 2 days after the
initial thrombolysis, which was re-opened with CDT and an
additional stent was placed in the external iliac vein.
Three patients suffered further episodes of DVT. In two
of the patients, this was after 2 and 3 years, respectively,
after cessation of anticoagulation treatment, involving the
popliteal and crural veins, and was not suitable for re-
thrombolysis. The last patient re-thrombosed about 1 year
after the initial thrombolysis but was re-thrombolysed
successfully. However, a re-thrombosis occurred again
later, but re-thrombolysis was not attempted due to poor
compliance to her anticoagulation treatment.
Failures with reflux
Deep reflux developed in six patients with patent veins
during the follow-up period. Of these, one patient had reflux
in both the femoral and thepopliteal vein, onepatient only in
the femoral vein, and the rest only in the popliteal vein.
Open veins without reflux
Fig. 1 shows the results for all treated patients (intention to
treat, ITT) with patent veins and normal valves after 6
years in 82% of the limbs. Fig. 2 shows an increased rate of
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protocol (Table 3).
Post-thrombotic symptoms
All patients with patent veins and normal valve function
showed no sign of dermal pigmentation, ulceration or venous
claudication at follow-up. In this group, seven patients had
slight oedema, according to the CEAP clinical class C-3; of
these, five had superficial reflux (four great saphenous vein
and one small saphenous vein). Three other patients had
a slight feeling of heaviness in their affected limb.
Discussion
The long-term results in this prospective single-centre
clinical series of acute IFVT treated with CDT are still
excellent in comparison with our first published series in
2005.7 Open veins without reflux were achieved in 82% of
the affected lower extremities after 6 years without any
mortality, or new PE and only a few cases of new DVT. The
patients with restored venous iliofemoral segments showed
no sign of PTS such as venous claudication, eczema or
ulceration.
To our knowledge, this study describes the largest clin-
ical series of this treatment with long-term follow-up in
which vein patency and freedom from reflux have been
evaluated. These are the factors that lead to severe
disability and economic liability for the patient, as well as
huge costs to society. Based on the observation that at least
60% of the cases with PTS symptoms will occur 2e3 yearsTable 3 The series of 101 patients with 103 limbs.
103 limbs intention to treat with CDT
2 limbs in the patient with cancer
4 limbs with chronic changes: SFV, CFV, SFVþ CFV,
stenotic SFV.
8 limbs with caval atresia
89 limbs treated per protocolafter the thrombotic event, the long follow-up interval in
this series gives evidence of a lasting effect.8
Mortality of 0.4% has been reported in The National
Venous Registry in 1999.9 PE has been reported in a few
papers in 1e13% of the treated cases.9e12 Major bleeding is
reported in up to 10% in some studies, but many papers
have reported only minor bleeding complications.
There is no consensus as to whether or not an IVC filter is
necessary. The figures for PE complications listed above
concern patients mostly free of thrombus involvement of
IVC. It has been shown that 22% of pelvic vein thromboses
propagate into the IVC without a higher risk for PE
compared with DVT in femoral or iliac vein segment
alone.13 In another paper, visible emboli in a retrievable
filter were found in almost half of the cases and most in
patients with a hypercoagulable state, not necessarily
causing symptomatic PE.14 However, a filter without emboli
may be the result of thrombus lysis within the filter by the
treatment given in the limb. Filter insertion itself may also
be troublesome. We decided to place a filter if thrombus
was found to be floating, in which case it was inserted from
the contralateral groin with great caution. This strategy
seems wise until further evidence is obtained. A situation
with a patient with poor pulmonary reserve due to earlier
PE could be an indication for filter placement.15
Our series included seven patients (eight legs) with
aplasia of the inferior vena cava. In the first case the
venogram revealed the diagnosis, which was in contrast to
what was suspected on ultrasound imaging, and led to
intervention with thrombolytic therapy. After the initial
successful treatment of the first patient, it was decided to
offer treatment to these patients outside the protocol, and
a total of seven patients (eight legs) were included in this
study. All these patients had patent veins without reflux at
follow-up. Very few papers have published results on this
treatment option.11,16
In our opinion, the use of intermittent pneumatic
compression (IPC) to these patients has been beneficial. It
has been shown in a small comparative study that the use of
IPC of the foot and calf during bed rest can reduce oedema
without increasing the risk of PE. IPC resulted in better
initial complete lysis, late patency and better valve func-
tion compared with that in the control group.17
In contrast to many other publications concerning IFVT,
this series excluded patients with thrombus affecting the
popliteal and calf veins. If these patients were included, it
would have had a negative impact on the results. The
untreated crural veins would not have been thrombolysed.9
Attempts to puncture and thrombolyse an occluded popli-
teal vein in cases of distal DVT is of no benefit to the patient
because one of the basic principles with CDT is to have
ongoing upstream blood flow to maintain the cleared vein
segments open during the procedure.18
Streptokinase has been abandoned due to the allergic
complications, and now urokinase, recombinant tissue
plasminogen activator or reteplase are used in the pub-
lished trials. One paper demonstrated no difference in the
results concerning safety or efficacy of these drugs.19
There are other conflicting areas comparing results after
CDT. Many series have included patients with cancer,
previous ipsilateral DVT and duration of symptoms prior to
treatment up to 4 weeks. This co-morbidity and symptoms
116 N. Bækgaard et al.of long duration may negatively affect the outcome, and
emphasise the importance of including a detailed descrip-
tion of the patients included in any published series. An
acute DVT should be defined as symptoms present for 14
days or less and/or imaging indicating the venous throm-
bosis having occurred within 14 days.15
Many series describe the outcome divided into vein
segments with complete or partial clot resolution. At 1 year,
the outcome might be twice as good, in terms of patent
veins, after initial total clot removal compared with partial
clot removal.9 The effort should be directed at removing all
of the thrombus, which was achieved in all our patients with
primary DVT. Ourmethods included replacing the catheter in
the remaining thrombus when necessary and then to
continue thrombolysis for additional 6 h after total clot
removal in cases of sustained elevation of D-dimer and to
insert a stent, even in cases with minor iliac stenosis.
One major bleeding complication occurred. The case
emphasises that a medical history, together with a very
careful objective investigation of the patient, is mandatory
before administering a thrombolytic agent. Another aspect
of these considerations to avoid bleeding episodes is the
use of a secure technique with US guidance for puncturing
the popliteal vein.
There are very few publications with long follow-up
comparable to our study. Work from 2001 compared
a group of 33 patients treated with anticoagulation alone
with a group of 18 patients treated with CDT. The
outcome presented in a KaplaneMeier plot showed 3
times better patency of 69% after 5 years for the group
treated with CDT. Reflux was not mentioned as an
endpoint. Long-term symptom resolution was 78% in the
CDT group compared with 30% in the group treated with
anticoagulation.20 A more recent publication reporting
the outcome in 34 patients showed poor results with
occlusion in almost 60% of the stents after 3 years. A stent
longer than 6 cm was found to be the cause of failure, but
there were severe methodological problems.18 Reflux was
found in 32% after 24 months in another study with 28
patients.11
In a study with almost comparable groups, the patients
treated with CDT experienced better quality of life (QOL)
compared with patients treated with anticoagulation alone
after median 22 months of follow-up.21
A randomised controlled trial (RCT) published in 2002
compared CDT in a group of 18 patients with a group of 17
patients treated with anticoagulation. After a short follow-
up time of 6 months, the CDT group had a patency rate of
72% compared with 12% in the group treated with anti-
coagulation. The outcome of venous reflux assessments
mirrored those of patency, which were 12% compared with
41% in favour of CDT.22
Another recently published and still ongoing RCT from
Norway (the CaVenT study) with 50 patients treated with
CDT and 53 patients in the control group receiving standard
treatment alone did not demonstrate the same convincing
results as the RCT from 2002. At 6 months, patency of the
iliofemoral segment was 64% in the CDT group and 36% in
the control group corresponding to an absolute risk reduc-
tion of 28%. Femoral venous incompetence was found in
60% and 66% among the CDT-treated patients and controls,
respectively. No significant correlation was found betweenthe lysis grade or use of additional angioplasty/stent and 6
months’ patency.23Conclusion
Patent veins without reflux were achieved in 82% of
patients affected by iliofemoral venous thrombosis treated
with CDT after a median of 50 months of follow-up. For
patients strictly following the protocol, the result was 86%.
This clinical series of 101 patients had very strict inclusion
criteria for inclusion, which proved to be very efficient in
reducing the post-thrombotic complex of symptoms,
compared with traditional anticoagulation alone. We
strongly recommend that future reports present results
using survival statistics, as a KaplaneMeier plot of compe-
tent veins, defined as open veins without reflux. Future
RCTs will show if anticoagulation alone still has a role for
this selected group of patients.Conflict of Interest/Funding
None.
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